111, Inc. Partners with world’s largest Italian biopharmaceutical company A. Menarini China Holding Co., Ltd to expand the distribution channel.
111, Inc., a leading integrated online and offline healthcare platform, announced that it has established a strategic partnership with A. Menarini China Holding Co., Ltd, the subsidiary of Menarini Group in China. Menarini Group is the world’s largest Italian biopharmaceutical company and is present in over 130 countries worldwide. 111 will work together with Menarini to develop new retail distribution channels and expand distribution of its product offerings leveraging 111’s technology and leading platform capabilities.
Expanding the retail presence
This partnership will make the Company a primary distributor of Menarini’s products in China as the platform offers cost-effective online retail for customers. “1 Drug Mall” (online wholesale pharmacy) will support Menarini in expanding its retail presence and increase brand recognition in China’s consumer market. Menarini will leverage customized channel management, powerful data intelligence, customer analytics, and extensive networks through 111’s platforms. Menarini’s consortium of skilled medical professionals will provide academic knowledge and training to 111 while 111 will offer e-prescription services for Menarini products at 111’s internet hospital “1 Clinic.”
China’s online pharmaceutical and healthcare services remains strong as favorable policies continue to open the market. The governments’ confidence in major market leaders like 111, who have proven they have the ability to maintain high standards of professionalism, have allowed for growth in services such as online medical consultation and prescription processing. The increase of digital healthcare services also alleviates strain on China’s healthcare system as access becomes easier.
Dr. Gang Yu, Co-Founder and Executive Chairman of 111, stated, “We are impressed by Menarini’s outstanding R&D and high-quality production capabilities, and look forward to their contribution to our platform. We are confident in our ability to further advance our partnerships and platform offerings as we continue to focus on building our core competencies in cloud-services, smart supply chain, big data analytics and medical industry expertise.”
